Homoharringtonine May be ‘Better Alternative’ to Etoposide In Pediatric AML
Use of homoharringtonine (HHT) may result in improved responses among patients with pediatric acute myeloid leukemia (AML) compared with etoposide-based induction therapy, according to findings from a study published in the Journal of Clinical Oncology.
Comments